EXTENDED REPORT

Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

H Sakaguchi, Y Ikuno, F Gomi, M Kamei, M Sawa, M Tsujikawa, Y Oshima, S Kusaka and Y Tano

Department of Ophthalmology, Osaka University Medical School, Suita, Japan

Correspondence to:
Correspondence to:
Y Ikuno
Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, E7, Suita, Osaka 565-0871, Japan; ikuno{at}ophthal.med.osaka-u.ac.jp

Aim: To assess the efficacy and safety of an intravitreal injection of bevacizumab (Avastin®) for myopic choroidal neovascularisation (mCNV).

Methods: Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months.

Results: The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed.

Conclusion: Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.

Abbreviations: AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; mCNV, myopic choroidal neovascularisation; OCT, optical coherence tomography; PDT, photodynamic therapy; VEGF, vascular endothelial growth factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues

P J Rosenfeld
Br. J. Ophthalmol. 2007 91: 128-130. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Takahashi, K., Saishin, Y., Saishin, Y., King, A. G., Levin, R., Campochiaro, P. A. (2009). Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib. Arch Ophthalmol 127: 494-499 [Abstract] [Full Text]  
• Ruiz-Moreno, J M, Montero, J A, Gomez-Ulla, F, Ares, S (2009). Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br. J. Ophthalmol. 93: 448-451 [Abstract] [Full Text]  
• Chan, W-M, Lai, T Y Y, Liu, D T L, Lam, D S C (2009). Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br. J. Ophthalmol. 93: 150-154 [Abstract] [Full Text]  
• Kuo, I. C., Haller, J. A., Maffrand, R., Sambuelli, R. H., Reviglio, V. E. (2008). Regression of a Subfoveal Choroidal Metastasis of Colorectal Carcinoma After Intravitreous Bevacizumab Treatment. Arch Ophthalmol 126: 1311-1313 [Full Text]  
• Wong, D., Li, K. K W (2008). Avastin in myopic choroidal neovascularisation: is age the limit?. Br. J. Ophthalmol. 92: 1011-1012 [Full Text]  
• Arias, L, Planas, N, Prades, S, Caminal, J M, Rubio, M, Pujol, O, Roca, G (2008). Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br. J. Ophthalmol. 92: 1035-1039 [Abstract] [Full Text]  
• Keane, P A, Liakopoulos, S, Chang, K T, Heussen, F M, Ongchin, S C, Walsh, A C, Sadda, S R (2008). Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br. J. Ophthalmol. 92: 1081-1085 [Abstract] [Full Text]  
• Chang, L. K., Spaide, R. F., Brue, C., Freund, K. B., Klancnik, J. M. Jr, Slakter, J. S. (2008). Bevacizumab Treatment for Subfoveal Choroidal Neovascularization From Causes Other Than Age-Related Macular Degeneration. Arch Ophthalmol 126: 941-945 [Abstract] [Full Text]  
• Gomi, F, Sawa, M, Sakaguchi, H, Tsujikawa, M, Oshima, Y, Kamei, M, Tano, Y (2008). Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 92: 70-73 [Abstract] [Full Text]  
• Lynch, S. S, Cheng, C. M (2007). Bevacizumab for Neovascular Ocular Diseases. The Annals of Pharmacotherapy 41: 614-625 [Abstract] [Full Text]  
• Rosenfeld, P J (2007). Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br. J. Ophthalmol. 91: 128-130 [Full Text]